Last reviewed · How we verify
biphasic insulin aspart 30
Biphasic insulin aspart 30 is a premixed insulin that combines rapid-acting insulin aspart with intermediate-acting insulin to provide both immediate and sustained blood glucose control.
Biphasic insulin aspart 30 is a premixed insulin that combines rapid-acting insulin aspart with intermediate-acting insulin to provide both immediate and sustained blood glucose control. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | biphasic insulin aspart 30 |
|---|---|
| Also known as | NovoMix® 30, BIASP, BIAsp30, Novolog Mix70/30, NovoLog® Mix 70/30 |
| Sponsor | Novo Nordisk A/S |
| Drug class | Insulin (premixed biphasic) |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
This formulation contains 30% rapid-acting insulin aspart and 70% intermediate-acting insulin aspart protamine suspension. The rapid-acting component begins working within 10-20 minutes to address postprandial (after-meal) glucose spikes, while the intermediate-acting component provides basal insulin coverage over several hours. Together, they mimic a more physiologic insulin secretion pattern in patients with type 1 and type 2 diabetes.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes
- INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study (PHASE4)
- Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs (PHASE4)
- Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus. (PHASE3)
- Bioequivalence Study of INS062 and Pharmacokinetics and Pharmacokinetics Study of Single Injection of HR20014 in Healthy Subjects (PHASE1)
- Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy (PHASE4)
- Comparison of Premixed Insulins Aspart 30, Aspart 70 and Aspart on Postprandial Lipids (PHASE4)
- Premixed vs Basal Bolus Insulin Therapy in Older Patients With Type 2 Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |